Table 2.
Disease-free survival and overall survival comparisons between treatment arms (efficacy cohort [N = 40])
| Survivala | Disease-free survival (months) | Overall survival (months) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Arm | Median follow-up (mo) | Events | Median (95% CI) | HR (95% CI) p value | Events | Median (95% CI) | HR (95% CI) p value | ||
| Cy-GVAX (n = 16) | 23.1 | 12 | 13.90 (5.59, NR) | Ref. | 0.92 (0.42–2.02) p = 0.829 | 12 | 23.59 (13.27, NR) | Ref. | 0.90 (0.38–2.14) p = 0.813 |
| Cy-GVAX PD-1 (n = 14) | 26.1 | 13 | 14.98 (7.95, 44.09) | 1.09 (0.50–2.40) p = 0.829 | Ref. | 11 | 27.01 (20.76, NR) | 1.11 (0.47–2.63) p = 0.813 | Ref. |
| Cy-GVAX PD-1 CD137 (n = 10) | 31.6 | 6 | 33.51 (16.76, NR) | 0.55 (0.21–1.49) p = 0.242 | 0.51 (0.19-1.35) p = 0.173 | 4 | 35.55 (17.74, NR) | 0.59 (0.18–1.91) p = 0.377 | 0.53 (0.17–1.67) p = 0.279 |
aSurvival measured from date of first [neoadjuvant] study treatment; cox regression utilized. NR not reportable.